Literature DB >> 2234096

Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

S J MacLennan1, G R Martin.   

Abstract

This report describes the actions of the non-peptide ergot alkaloids methysergide, methylergometrine and ergometrine at two types of 5-HT receptor mediating vascular contraction; the well established 5-HT2 receptor in rabbit aorta and a non-5-HT2 receptor in rabbit saphenous vein which resembles the 5-HT1-like receptor in dog saphenous vein. In the rabbit aorta ergometrine (1 mumol/l) and methylergometrine (0.3 mumol/l), but not methysergide, produced small contractions (14% and 7% respectively of the maximal response to 5-HT). This contraction was not related to activation of 5-HT2 receptors since it was resistant to blockade by ketanserin (0.3 mumol/l). When examined as antagonists of 5-HT-induced contractions of rabbit aorta, each ergot displayed nanomolar affinity at the 5-HT2 receptor but only methysergide behaved as a simple competitive antagonist (pKB = 8.25). Methylergometrine and ergometrine produced surmountable blockade which was accompanied by a non-parallel displacement of the 5-HT concentration-effect curves. The selective 5-HT1-like receptor agonist GR43175 (less than or equal to 30 mumol/l) was devoid of affinity at the 5-HT2 receptor in rabbit aorta. In the rabbit saphenous vein each of the ergots produced concentration-dependent contractions which resulted in overtly biphasic concentration-effect curves. Only the first phase of contraction mimicked the effects of 5-HT and GR43175 since contractions were not blocked by MDL 72222 (1 mumol/l), but were surmountably antagonised by methiothepin (10 nmol/l), ketanserin (0.3 mumol/l) and spiperone (0.3 mumol/l).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2234096     DOI: 10.1007/bf00166953

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  56 in total

1.  Effect of serotonin in migraine patients.

Authors:  R W KIMBALL; A P FRIEDMAN; E VALLEJO
Journal:  Neurology       Date:  1960-02       Impact factor: 9.910

Review 2.  5-HT receptors in the coronary circulation.

Authors:  J A Angus
Journal:  Trends Pharmacol Sci       Date:  1989-03       Impact factor: 14.819

3.  An attempt at selective protection from phenoxybenzamine of postjunctional alpha-adrenoceptor subtypes mediating contractions to noradrenaline in the rabbit isolated saphenous vein.

Authors:  C J Daly; W R Dunn; J C McGrath; V G Wilson
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

4.  Quantification of H2-agonism by clonidine and dimaprit in an adenylate cyclase assay.

Authors:  D G Trist; P Leff
Journal:  Agents Actions       Date:  1985-04

5.  The kinetics of 14C-GR43175 in rat and dog.

Authors:  F A Dallas; C M Dixon; R J McCulloch; D A Saynor
Journal:  Cephalalgia       Date:  1989       Impact factor: 6.292

6.  Mechanism of the indirect sympathomimetic effect of 5-hydroxytrypt-amine on the isolated heart of the rabbit.

Authors:  J R Fozard; G M Mwaluko
Journal:  Br J Pharmacol       Date:  1976-05       Impact factor: 8.739

7.  A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists.

Authors:  W Feniuk; P P Humphrey; M J Perren; A D Watts
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

8.  Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine.

Authors:  A Doenicke; J Brand; V L Perrin
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

9.  Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography.

Authors:  M E Bertrand; J M LaBlanche; P Y Tilmant; F A Thieuleux; M R Delforge; A G Carre; P Asseman; B Berzin; C Libersa; J M Laurent
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

10.  Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists?

Authors:  P Leff; G R Martin
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

View more
  8 in total

Review 1.  Drug interactions with triptans : which are clinically significant?

Authors:  Paul E Rolan
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

2.  Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.

Authors:  M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

Review 3.  5-HT2 receptor antagonists and migraine therapy.

Authors:  E J Mylecharane
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

4.  Reversible cerebral vasoconstriction syndrome with limb myoclonus following intravenous administration of methylergometrine.

Authors:  Tomoko Ishibashi; Satoru Ishibashi; Tokujiro Uchida; Koichi Nakazawa; Koshi Makita
Journal:  J Anesth       Date:  2011-03-23       Impact factor: 2.078

5.  Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.

Authors:  T M Cocks; B K Kemp; D Pruneau; J A Angus
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  5-Hydroxytryptamine (5-HT) contracts the guinea-pig isolated iliac artery via 5-HT1-like and 5-HT2 receptors.

Authors:  H Pertz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

7.  Vasoactive Effects of Acute Ergot Exposure in Sheep.

Authors:  Rossalin Yonpiam; Jair Gobbet; Ashok Jadhav; Kaushik Desai; Barry Blakley; Ahmad Al-Dissi
Journal:  Toxins (Basel)       Date:  2021-04-20       Impact factor: 4.546

8.  Sustained vascular contractile response induced by an R- and S-epimer of the ergot alkaloid ergocristine and attenuation by a noncompetitive antagonist.

Authors:  Jensen E Cherewyk; Sarah E Parker; Barry R Blakley; Ahmad N Al-Dissi
Journal:  J Anim Sci       Date:  2022-09-01       Impact factor: 3.338

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.